All In Biotech

Free tool

FAERS Monitor: Idarubicin Hydrochloride

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050734 or its brand name (Idarubicin Hydrochloride, Idarubicin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,159

Serious

1,145

99% of reports

Hospitalization

475

Death reported

253

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • myelosuppression195
  • febrile neutropenia152
  • pyrexia100
  • off label use66
  • white blood cell count decreased62
  • pneumonia61
  • platelet count decreased54
  • infection53
  • neutropenia51
  • neutrophil count decreased49
  • nausea46
  • death43
  • sepsis39
  • acute myeloid leukaemia38
  • drug ineffective36

Reports by year received

View as table
YearReports
20041
20052
20062
20073
20082
20097
20108
201136
201227
201310
201416
201532
201616
201733
201860
201952
202046
202177
2022155
2023185
2024140
2025149
2026100

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,000 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myelosuppressionSignal19598.886.918,707
acute myeloid leukaemiaSignal3844.432.41,565
febrile neutropeniaSignal15241.735.95,999
neutrophil count decreasedSignal4921.816.6954
white blood cell count decreasedSignal6210.48.2519
platelet count decreasedSignal549.27.1388
neutropeniaSignal516.85.2248
infectionSignal536.65.1250
sepsisSignal396.34.7171
pyrexiaSignal1005.24.3345
pneumoniaSignal613.42.7104
off label use661.41.16
nausea461.10.80
death430.90.70
drug ineffective360.50.419

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.